Comparative Pharmacology
Head-to-head clinical analysis: GENGRAF versus LUPKYNIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENGRAF versus LUPKYNIS.
GENGRAF vs LUPKYNIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcineurin inhibitor; binds to cyclophilin, inhibits calcineurin-dependent T-cell activation, preventing nuclear factor of activated T-cells (NF-AT) dephosphorylation and translocation, thereby reducing IL-2 and other cytokine gene transcription.
Calcineurin inhibitor immunosuppressant that binds to cyclophilin A, inhibiting calcineurin activity, which prevents dephosphorylation and activation of nuclear factor of activated T-cells (NFAT), thereby reducing cytokine production and T-cell activation.
5-15 mg/kg/day orally in divided doses every 12 hours.
23.7 mg orally twice daily with food.
None Documented
None Documented
Terminal half-life is approximately 8.4 hours (range 5-18 hours) in adult volunteers; prolonged in hepatic impairment.
Terminal elimination half-life approximately 30 hours; supports once-daily dosing; steady-state reached by day 4.
Primarily biliary/fecal (94%); renal excretion accounts for 6% (0.1% unchanged).
Primarily hepatic metabolism; <1% excreted unchanged in urine; approximately 66% of total radioactivity recovered in feces (mainly metabolites) and 22% in urine (mainly metabolites).
Category C
Category C
Calcineurin Inhibitor Immunosuppressant
Calcineurin Inhibitor Immunosuppressant